Abstract: The present invention relates to new prostaglandin derivatives having improved pharmacological activity and enhanced tolerability. They can be employed for the treatment of glaucoma and ocular hypertension.

Abstract: The present invention relates to novel compounds that are nuclear transcription factors (NTF) regulators. The present invention also provides methods for treating, preventing and/or reducing inflammation associated diseases by regulating NTF in the cardiovascular, connective tissue, pulmonary, gastrointestinal, respiratory, urogenital, nervous, or cutaneous systems as well as tumoral and infective diseases employing said compounds.

Abstract: Compounds of formula (I) wherein R1 is H, C1-C3-alkyl, C3-C5-cycloalkyl or C1-C3-perfluoroalkyl, R2 is H, C1-C6-alkyl optionally substituted by OH, C1-C3-alkoxy or C1-C3-perfluoroalkyl, R3 is C1-C6-alkyl, C3-C6-alkenyl, C3-C6-alkinyl, C3-C7-cycloalkyl, C1-C6-perfluoroalkyl or C3-C6-cycloalkyl-C1-C6-alkyl, R4=H, ADT-OH, cysteine, agmatine, arginine, aminoguanidine or agents releasing or stimulating the release of hydrogen sulfide, and salts thereof. The compounds are suitable for treating impotence, cardiovascular disorders, diseases characterized by disorders of gut motility, gastropathy of diabetic and nondiabetic origin, in general diseases where cytoprotection is important.

Abstract: Compounds of general formula: wherein R?, R, x and z have the meaning reported in the specification, are useful for treating inflammatory diseases including metabolic syndrome, diabetes, obesity, dyslipidemia, and insulin resistance.

Abstract: New 4-aminoquinoline derivatives having the general formula (I) wherein R, M, X, Y and T have the meaning described in the specification, as potent antimalarials active also on chloroquine-resistant Plasmodium falciparum malaria strains.